Pulse Biosciences, Inc. (PLSE)
NASDAQ: PLSE · Real-Time Price · USD
15.98
-0.12 (-0.75%)
Oct 4, 2024, 4:00 PM EDT - Market closed

Company Description

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company.

The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.

The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015.

Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.

Pulse Biosciences, Inc.
Pulse Biosciences logo
Country United States
Founded 2014
IPO Date May 18, 2016
Industry Medical Instruments & Supplies
Sector Healthcare
Employees 56
CEO Burke Barrett

Contact Details

Address:
3957 Point Eden Way
Hayward, California 94545
United States
Phone 510 906 4600
Website pulsebiosciences.com

Stock Details

Ticker Symbol PLSE
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001625101
CUSIP Number 74587B101
ISIN Number US74587B1017
Employer ID 46-5696597
SIC Code 3841

Key Executives

Name Position
Burke T. Barrett President, Chief Executive Officer and Director
Robert W. Duggan Executive Co-Chairman
Darrin R. Uecker Chief Technology Officer and Director
Mitchell E. Levinson Chief Strategy Officer
Kevin P. Danahy Chief Commercial Officer
Edison Manuel Vice President of Operations
Dr. Richard Nuccitelli Ph.D. Chief Science Officer
Kenneth B. Stratton Esq., J.D. General Counsel and Corporate Secretary
Patty Perla Vice President of Human Resources
David Danitz Senior Vice President of Engineering

Latest SEC Filings

Date Type Title
Aug 19, 2024 10-Q Quarterly Report
Aug 15, 2024 NT 10-Q Notification of inability to timely file Form 10-Q or 10-QSB
Aug 12, 2024 8-K Current Report
Aug 12, 2024 8-K Current Report
Aug 8, 2024 8-K Current Report
Jul 15, 2024 8-K Current Report
Jul 15, 2024 424B5 Filing
Jul 15, 2024 S-3MEF Filing
Jul 8, 2024 8-K Current Report
Jul 8, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership